富邦股份分析师会议 调研日期：2025年08月26日 调研行业：化肥行业 参与调研的机构：通过全景网路演互动平台参加公司2025年半年 度网上业绩说明会的投资者等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | ...

2025年8月20-22日，第四届合成生物与绿色生物制造大会（SynBioCon 2025）于浙江宁波召开。这场以"生物制造赋能未来"为核心的行业峰会， 汇聚了全球顶尖科研机构与产业领袖。 中国健康食用油领域的突破者—— 轻云减负油 ，凭借" 生物科技重构油脂产业 "的创新实践成为焦点。其 联合创始人兼CTO贺林博士 受邀发表主题 演讲， 公布与北京大学医学部合作的百人规模甘油二酯（DAG）临床研究成果 ，以硬核数据宣告 ：合成生物技术正推动食用油产业进入"代谢减负时 代" 。 技术破局：生物酶解重构油脂分子 从 "易囤积"到"代谢友好"的进化 传统食用油的加工理念通常可概括为 "提高纯度，牺牲营养"。这类油通过高温精炼工艺去除杂质，却也在这一过程中破坏了油脂中的天然活性成分。 此外，传统油脂中甘油三酯（TAG）"易囤积的脂肪"含量超过95%，其代谢需经肠壁吸收进入血液循环，最终以脂肪形式储存于体内。长期过量摄入易 引发脂肪堆积和胰岛素抵抗。相比之下，生物技术所倡导的油脂加工逻辑更倾向于"精准改造，保留精华"。 以轻云减负油为例，该产品依托自主研发的 生物酶解工艺 ，在低温条件下将天然甘油三酯转化为 甘油二酯 ...

Core Viewpoint - The food industry is leveraging digital transformation to accelerate its upgrade and capture new market opportunities amid changing consumer demands in the digital economy era [1] Industry Overview - The food industry, as a pillar of the national economy, is undergoing rapid transformation driven by digitalization, enhancing production efficiency and product quality [3][7] - Key industrial enterprises in China's food sector have achieved a numerical control rate of 63.3% and a digital design tool penetration rate of 72.8% [3] Digital Transformation - Leading companies in the food industry are adopting digital technologies to improve production processes and meet consumer demands for safety and health [3][5] - Hai Tian Wei Ye, a representative in the condiment sector, is integrating smart manufacturing technologies while maintaining traditional brewing methods [4][5] - Anqi Yeast has also embraced digital control technologies to enhance product quality and reduce resource consumption [5][6] Consumer Trends - The rise of health-conscious consumers is creating new market opportunities, prompting companies to develop targeted products for various demographics [7][8] - Hai Tian Wei Ye has expanded its product matrix from 400 to 1400, focusing on nutrition and health [7] - Anqi Yeast is developing new products aimed at specific consumer groups, including the elderly and young people [8] Investment Opportunities - The food and beverage sector is seen as a promising investment area due to the ongoing consumer upgrade trend, with companies leveraging AI and digital technologies to enhance efficiency and product quality [6][8] - Analysts suggest that leading companies in the consumer sector are currently undervalued, with potential for valuation recovery as digital technologies are integrated [6][7]

公司拥有商业化规模的生产能力，并推行"两抗"战略，开发抗体药物和抗生素的皮下制剂。公司的业务 模式结合了自主研发与外部合作，并具备成本效益和标准化生产能力。 （文章来源：证券时报网） 宝济药业是一家临床阶段的生物技术公司，专注于利用合成生物技术在中国开发重组生物药物。公司拥 有涵盖四个治疗领域的七款候选药物，包括三款核心产品KJ017、KJ103和SJ02，以及五项临床前资 产。 核心产品在全球范围内受知识产权保护，拥有9项授权专利和10项专利申请。KJ017用于大容量皮下给 药，KJ103用于治疗自身免疫性疾病，SJ02用于辅助生殖。所有核心产品均已在中国进入临床后期阶段 或NDA注册阶段。 宝济药业已向港交所提交上市申请。中信证券、海通国际为其联席保荐人。 ...

据港交所8月21日披露，上海宝济药业股份有限公司-B(简称：宝济药业)向港交所主板递交上市申请， 中信证券、海通国际为其联席保荐人。这是该公司年内第二次递表。 | [編纂]的[編纂]數目 :[編纂]股H股(視乎[編纂] | | | | --- | --- | --- | | 行使與否而定) | | | | [編纂]數目 | .. | [編纂]股H股(可予[編纂]) | | [編纂]數目 | .. | [編纂]股H股(可予[編纂]及 | | 視乎[編纂]行使與否而定) | | | | 最高[編纂] : | | 每股H股[編纂]港元,另加1.0%經紀 | | 佣金、0.00015%會財局交易徵費、 | | | | 0.0027%證監會交易徵費及0.00565% | | | | 聯交所交易費(須於[編纂]時以港元 | | | | 繳足,多繳股款可予退還) | | | | 面值 | : | 每股H股人民幣0.20元 | | [編纂] : [編纂] | | | | 聯席保薦人·[編纂]·[編纂]·[編纂] | | | | | 截至12月31日止年度 | | 截至6月30日止六個月 | | --- | --- | --- ...

Core Viewpoint - The synthetic biology sector in food and agriculture has entered a period of explosive investment and development, focusing on the production of alternative proteins and other innovative food products [2]. Group 1: Investment and Development Trends - The application of synthetic biology in food nutrition is increasing annually, with a focus on products such as edible microbial proteins, functional sugars, probiotics, human milk oligosaccharides, EPA, DHA, collagen, and cultured meat [2]. - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference will be held from August 20-22 in Ningbo, Zhejiang, featuring representatives from various universities and companies sharing insights on synthetic biology technology and product development [3]. Group 2: Conference Agenda Highlights - The conference will include sessions on innovative research and industrial transformation of probiotics, bio-manufacturing of human milk oligosaccharides, and the development of vitamins and agricultural enhancers [6][19][39]. - Notable speakers include experts from Jiangnan University, Yili Group, and other leading companies in the field, discussing topics such as sweet proteins and green agricultural enhancers [6][39]. Group 3: Industry Collaboration and Support - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd., in collaboration with various academic and research institutions, highlighting the importance of industry-academia partnerships in advancing synthetic biology [9][10]. - Strategic cooperation with media and industry alliances is emphasized to promote the growth of the synthetic biology sector [10][31].

Group 1 - The Ministry of Industry and Information Technology has announced the first batch of landmark products in biomanufacturing, with Nanjing Xuankai Biotechnology Co., Ltd.'s "γ-Polyglutamic Acid" being the only product selected from Jiangsu Province [1] - A total of 36 products were included in the first batch, covering various fields such as food, feed additives, biobased materials, biopharmaceuticals, natural product biosynthesis, biobased chemicals, and cosmetics, with representation from over 20 provinces across the country [1] - "γ-Polyglutamic Acid" is recognized as a high-tech product in Jiangsu Province and is widely used in agriculture, medicine, food, environmental protection, and daily chemicals due to its bioactivity, safety, non-toxicity, and full biodegradability [1] Group 2 - Xuankai Biotechnology has established production capacity exceeding 10,000 tons, with a fermentation capacity of 1,500 cubic meters, ranking first in the niche market of polyglutamic acid in China, holding over 60% market share, and is currently the largest global supplier of γ-Polyglutamic Acid [2] - Biomanufacturing is becoming a crucial aspect of China's strategy to enhance manufacturing capabilities and develop new productive forces, with synthetic biology identified as a core driving force [2] - Jiangsu Province is focusing on building an innovative hub for the synthetic biology industry, with the establishment of the Jiangsu Synthetic Biology Research Center, which will conduct interdisciplinary research led by three academicians from the Chinese Academy of Engineering [2]

【SynBioCon】 获 悉 ，8月，微元合成与全球最大的食品和配料企业嘉吉正式签署合作协议。 嘉吉 将作为微元阿洛酮糖产品在中国市场的重要经销 伙伴 ，携手推动该产品在多元食品应用场景中的市场拓展。 未来食品&农业 | 微元合成 此次签约标志着双方将围绕 "更健康、更低热量、更具风味" 的产品创新需求展开深度合作，共同助力食品行业实现可持续升级。 近期，阿洛酮糖（Allulose）已获得国家相关部门的批准，作为新食品原料正式在中国市场开展应用。作为一种天然、低热量的稀有糖类，阿洛酮糖甜 味纯正，不仅具备与蔗糖相近的口感体验，更在血糖响应、能量摄入控制等方面展现出显著优势。 点击更多阅读 ： 全国首家！下一代爆款甜味剂获批！ 微元作为全球唯一采用发酵工艺生产阿洛酮糖的企业，不仅率先获得了中国首个行政许可，也是目前唯一取得生产许可证的阿洛酮糖生产企业 。 凭借领先的合成生物技术与绿色生物制造体系，微元已建立从生物发酵到纯化分离的高效生产链条。其阿洛酮糖产品具备纯度高、感官好、适用范围广 等优势，广泛适用于功能饮料、乳品、糖果、烘焙等品类。 作为此次合作的重要伙伴，嘉吉将依托其强大的B2B平台资源、多元化客户网 ...

Group 1 - The trend in the investment market shows a sustained interest in smart robotics, advanced manufacturing, and innovative pharmaceuticals, with significant financing activities reported [1] - Shanghai Fangqing Technology completed several hundred million RMB in angel round financing, focusing on AI computing [16] - Shanghai Chengfan Pharmaceutical announced over $60 million in Pre-A+ financing, led by Shunwei Capital, to advance its drug development pipeline [7] Group 2 - From July 28 to August 3, 22 financing events occurred in the domestic primary market, with a total scale of approximately 3.873 billion RMB [2] - The semiconductor/chip sector completed 4 financing rounds totaling nearly 500 million RMB, while the robotics sector also saw 4 rounds totaling nearly 400 million RMB [3] Group 3 - Jiangsu Province, Beijing, and Shanghai were the top regions for financing activities, with 6, 5, and 4 cases respectively [4] - Active investment institutions included Huatai Zijin, Yahui Investment, and Lingang Science and Technology Investment, each participating in 2 financing rounds [5] Group 4 - Shenzhen Xinglian Future Technology completed several million RMB in Pre-A financing, focusing on smart wearable technology for pets [6] - Suzhou Yinhang Biotechnology secured over 100 million RMB in financing to accelerate product commercialization and global market expansion [8] Group 5 - Nanjing Puli Meng Medical Technology completed nearly 300 million RMB in C round financing, focusing on high polymer materials and bioengineering [11] - Beijing Ruisi Zhili Technology announced several million RMB in financing to enhance AI infrastructure development [12] Group 6 - Nova Fusion Energy Technology completed 500 million RMB in angel round financing, focusing on small modular nuclear fusion commercialization [31] - Taohu Xingyun Technology secured over 50 million RMB in A round financing to advance its satellite development and deployment [18]

7月30日，科创板上市公司华恒生物（688639.SH）发布公告，披露公司正在筹划发行境外股份（H股） 并在香港联合交易所有限公司主板上市。 公开资料显示，华恒生物于2021年在A股上市，是一家以合成生物技术为核心，主要从事生物基产品的 研发、生产、销售的国家高新技术企业。 截至目前，公司主要产品包括氨基酸系列产品（丙氨酸系列、L-缬氨酸、异亮氨酸、色氨酸、精氨 酸）、维生素系列产品（D-泛酸钙、D-泛醇、肌醇）、生物基新材料单体（1,3-丙二醇、丁二酸）和其 他产品(苹果酸、熊果苷）等，可广泛应用于中间体、动物营养、日化护理、功能食品与营养、植物营 养等众多领域。 公告称，为深入推进公司全球化发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借 助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公司治理水平和综合 实力，正在筹划发行境外股份（H股）并在香港联合交易所有限公司（以下简称"香港联交所"）上市事 宜（以下简称"本次H股上市"）。 公司正与相关中介机构就本次H股上市的具体推进工作进行商讨，相关细节尚未确定，本次H股上市不 会导致公司控股股东和实际控制人发生变化。 公司 ...